Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Investigational MET inhibitors to treat Renal cell carcinoma.  Expert Opinion on Investigational Drugs.  28:851-860. 2019
2019 Correction to: Immunotherapy Advances in Urothelial Carcinoma (Current Treatment Options in Oncology, (2018), 19, 12, (79), 10.1007/s11864-018-0598-x).  Current Treatment Options in Oncology.  20. 2019
2019 Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.  Cancer.  125:1459-1469. 2019
2019 Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE).  Journal of Geriatric Oncology.  2019
2018 Correlation between Dt/V derived from ionic dialysance and blood-driven Kt/V of urea in African-American hemodialysis patients, based on body weight and ultrafiltration volume.  Clinical Kidney Journal.  11:734-741. 2018
2018 Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma.  Current Treatment Options in Oncology.  19. 2018
2017 Timing of androgen-deprivation therapy in prostate cancer.  Lancet Oncology.  18:e634. 2017
2017 Treatment approaches of hard-to-treat non-Hodgkin lymphomas.  Expert Review of Hematology.  10:259-273. 2017
2016 Bronchoscopy can be done safely in patients with thrombocytopenia.  Transfusion.  56:344-348. 2016
2016 Circulating biomarkers in bladder cancer.  Bladder cancer.  2:369-379. 2016
2014 Ectopic ACTH and cisplatin toxicity-a diagnostic dilemma.  American Journal of Therapeutics.  21:e154-e156. 2014
2013 A rare cause of dysphagia in a HIV patient - esophageal pseudodiverticulosis.  Acta Gastroenterologica Belgica.  76:340-341. 2013
2013 Sterile peritonitis because of splenic infarction in a patient on peritoneal dialysis: An unusual presentation.  Peritoneal Dialysis International.  33:339-340. 2013

Research Overview

  • Dr. Nandagopal’s primary clinic interest is interested in genitourinary (GU) malignancies. His research interests are in developing clinical trials for GU malignancies, and development of correlative and prognostic biomarkers.

    • Principal Investigator On

  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2019 - 2024
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC 2019 - 2024
  • Private Grant  awarded by MEDIVATION, INC 2019 - 2020

    • Investigator On

  • Private Grant  awarded by ADURO BIOTECH, INC. 2019 - 2024
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC 2019 - 2024
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC. 2019 - 2024
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2019 - 2024
  • Private Grant  awarded by ASTRAZENECA AB 2018 - 2023
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2022
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2022
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020

    • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), Tamil Nadu Doctor M.G.R. Medical University 2007

    • Full Name

  • Lakshminarayanan Nandagopal